Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.

about

Long-Term Outcome of Infliximab Optimization for Overcoming Immunogenicity in Patients with Inflammatory Bowel Disease.

Item

http://www.wikidata.org/entity/Q48230305

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Long-Term Outcome of Inflixima ...... th Inflammatory Bowel Disease.

@en

Long-Term Outcome of Inflixima ...... th Inflammatory Bowel Disease.

@nl

type

Item

label

Long-Term Outcome of Inflixima ...... th Inflammatory Bowel Disease.

@en

Long-Term Outcome of Inflixima ...... th Inflammatory Bowel Disease.

@nl

prefLabel

Long-Term Outcome of Inflixima ...... th Inflammatory Bowel Disease.

@en

Long-Term Outcome of Inflixima ...... th Inflammatory Bowel Disease.

@nl

P1476

Long-Term Outcome of Inflixima ...... th Inflammatory Bowel Disease.

@en

P2093

Adam S Cheifetz

http://www.w3.org/2001/XMLSchema#string

Mark T Osterman

http://www.w3.org/2001/XMLSchema#string

Ravy K Vajravelu

http://www.w3.org/2001/XMLSchema#string

P2860

Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview.

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.

Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: Adding value to current practice.

Use of anti-TNF drug levels to optimise patient management.

Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab.

Efficacy and Safety Profile of Anti-tumor Necrosis Factor-α Versus Anti-integrin Agents for the Treatment of Crohn's Disease: A Network Meta-analysis of Indirect Comparisons.

Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

P2888

s10620-018-4917-7

P304

761-767

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-018-4917-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

K Papamichael

P577

2018-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29340807

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

5823777

http://www.w3.org/2001/XMLSchema#string